A phase I study of human/mouse chimeric antiganglioside GD2 antibody ch14.18 in patients with neuroblastoma.
暂无分享,去创建一个
M. Schrappe | P. Reuland | T. Klingebiel | S. Gillies | R. Handgretinger | R. Reisfeld | P. Lang | D. Niethammer | R. Dopfer | K. Anderson | D. Neithammer | R. Handgretinger
[1] M. Urist,et al. Phase I trial of the murine monoclonal anti-GD2 antibody 14G2a in metastatic melanoma. , 1992, Cancer research.
[2] N. Berger,et al. Reassessment of patient response to monoclonal antibody 3F8. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] S. Gillies,et al. Enhancement of antibody-dependent cytotoxicity with a chimeric anti-GD2 antibody. , 1990, Journal of immunology.
[4] S. Gillies,et al. High-level expression of chimeric antibodies using adapted cDNA variable region cassettes. , 1989, Journal of immunological methods.
[5] T. Kipps,et al. Functional properties and effect on growth suppression of human neuroblastoma tumors by isotype switch variants of monoclonal antiganglioside GD2 antibody 14.18. , 1989, Cancer research.
[6] H. Wieland,et al. Gangliosides in normal human serum. Concentration, pattern and transport by lipoproteins. , 1989, European journal of biochemistry.
[7] M. Dyer,et al. Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype. , 1989, Blood.
[8] N. Berger,et al. Ganglioside GD2 specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] D. Cheresh,et al. Detection of ganglioside GD2 in tumor tissues and sera of neuroblastoma patients. , 1984, Cancer research.
[10] B. Spengler,et al. Morphology and growth, tumorigenicity, and cytogenetics of human neuroblastoma cells in continuous culture. , 1973, Cancer research.
[11] A. Evans,et al. A proposed staging for children with neuroblastoma. Children's cancer study group A , 1971, Cancer.
[12] J. Murray,et al. Phase I trial of murine monoclonal antibody 14G2a administered by prolonged intravenous infusion in patients with neuroectodermal tumors. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] W. Grizzle,et al. Phase I trial of the chimeric anti-GD2 monoclonal antibody ch14.18 in patients with malignant melanoma. , 1992, Human antibodies and hybridomas.
[14] A. Yu,et al. Effect of a chimeric anti-ganglioside GD2 antibody on cell-mediated lysis of human neuroblastoma cells. , 1991, Cancer research.
[15] R. Handgretinger,et al. Interferon-gamma upregulates the susceptibility of human neuroblastoma cells to interleukin-2-activated natural killer cells. , 1989, Natural immunity and cell growth regulation.
[16] F. Berthold,et al. Bone marrow transplantation in children with neuroblastoma. , 1989, Folia haematologica.
[17] F. Maul,et al. MIBG-treatment in neuroblastoma; experiences of the Tübingen/Frankfurt group. , 1988, Progress in clinical and biological research.
[18] D. Cheresh,et al. Human tumor antigens. , 1987, Advances in immunology.
[19] L. Nespoli,et al. The role of meta-iodo [131I]benzylguanidine (MIBG) in the diagnosis and follow-up of neuroblastoma. , 1986, Pediatric hematology and oncology.